Finalized policy for Medicare’s CAR-T inpatient reimbursement builds on policies solidified in las...
Avalere Cell & Gene Policy 360
Stay Informed to Support Cell and Gene Strategy
Expert insights on policy changes to understand the evolving market and drive strategic planning
Avalere Cell & Gene Policy 360 is your go-to source for anticipating the impact policy and market developments will have on innovative therapies. Understand how to monitor the environment, hone your strategy, and assess business impact.
This monthly update provides in-depth analysis from Avalere experts on developments specific to cell and gene therapies (CGTs) and broader policies with implications for CGTs, including FDA guidance, coverage and reimbursement decisions, drug pricing proposals, and innovative contracting flexibilities.
Stay informed of changes and their potential impact in order to support business planning, assess market opportunities, and identify early engagement opportunities.
Access to easy-to-navigate content with a summary description and “Avalere’s Take” on the most significant cell and gene policy developments.
Producing monthly updates and targeted insights on developments that affect cell and gene therapies, Megan West and a multidisciplinary team keep you informed by monitoring policy and regulatory changes with strategic business impacts.
Cell & Gene Policy 360 highlights guidance from the FDA, coding and reimbursement developments in the inpatient and outpatient settings of care, regulatory flexibilities for value-based arrangements, drug pricing proposals, and other timely developments.